Exosla Therapeutics

Exosla Therapeutics

Pre-clinical
Munich, GermanyFounded 2021exosla.com

Your browser does not support HTML5 video. Greatly improving neurological outcomes for newborn infants Pioneering immune-modulatory, off-the-shelf restorative medicine Science Multimodal signalling approaches are the future of immunotherapy, ranging from autoimmunity to tissue repair. However, they have been hindered by various scientific and manufacturing challenges, such as lack of adequate quality control and batch-to-batch

Founded
2021
Focus
Drug Delivery

About

Your browser does not support HTML5 video. Greatly improving neurological outcomes for newborn infants Pioneering immune-modulatory, off-the-shelf restorative medicine Science Multimodal signalling approaches are the future of immunotherapy, ranging from autoimmunity to tissue repair. However, they have been hindered by various scientific and manufacturing challenges, such as lack of adequate quality control and batch-to-batch

Funding History

1

Total raised: $4.5M

Seed$4.5MHigh-Tech GründerfondsMar 15, 2023

Company Info

TypePrivate
Founded2021
LocationMunich, Germany
StagePre-clinical

Contact

SIMILAR COMPANIES
300Microns
300Microns
Pre-clinical · Munich
BetaSense
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Mireca Medicines
Pre-clinical · Munich
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile